Bench-to-beside review: Acute-on-chronic liver failure - linking the gut, liver and systemic circulation

Critical Care

Volumn 15, Issue 5, 2011, Pages

  Verbeke, Len ^a   Nevens, Frederik ^a   Laleman, Wim ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; FLURBIPROFEN 4 NITROXYBUTYL ESTER; MONTELUKAST; NITRIC OXIDE; PRAZOSIN; SARTAN DERIVATIVE; TEZOSENTAN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE ON CHRONIC LIVER FAILURE; ADRENAL INSUFFICIENCY; ALCOHOL LIVER DISEASE; CIRCULATION; HUMAN; IMMUNOPATHOLOGY; INNATE IMMUNITY; INTESTINE; INTESTINE FLORA; INTESTINE MUCOSA PERMEABILITY; KUPFFER CELL; MORTALITY; MULTIPLE ORGAN FAILURE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STELLATE CELL; ACUTE LIVER FAILURE; BACTERIAL TRANSLOCATION; END STAGE LIVER DISEASE; GASTROINTESTINAL TRACT; IMMUNOLOGY; LIVER; MICROBIOLOGY; MICROCIRCULATION; VASCULARIZATION;

BACTERIAL TRANSLOCATION; END STAGE LIVER DISEASE; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; LIVER; LIVER FAILURE, ACUTE; MICROCIRCULATION;

EID: 81555229263     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10424     Document Type: Review

References (100)

1. Stange J, Ramlow W, Mitzner S, Schmidt R, Klinkmann H. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993, 17:809-813.
2. Jalan R, Williams R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options. Blood Purif 2002, 20:252-261. 10.1159/000047017, 11867872.
3. Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T, Nevens F. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut 2010, 59:1561-1569. 10.1136/gut.2009.189639, 20675694.
4. Hassanein TI, Tofteng F, Brown RS, McGuire B, Lynch P, Mehta R, Larsen FS, Gornbein J, Stange J, Blei AT. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007, 46:1853-1862. 10.1002/hep.21930, 17975845.
5. Flink HJ, Sprengers D, Hansen BE, van Zonneveld M, de Man RA, Schalm SW, Janssen HL, . HBV 99-01 Study Group Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005, 54:1604-1609. 10.1136/gut.2004.062208, 1774756, 15923670, HBV 99-01 Study Group.
6. Lee KH, Lee MK, Sutedja DS, Lim SG. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 2005, 25:973-977. 10.1111/j.1478-3231.2005.01091.x, 16162155.
7. Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, Siddiqui A, Jafri W. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002, 36:474-478.
8. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, de Silva HJ, Hamid SS, Jalan R, Komolmit P, Lau GK, Liu Q, Madan K, Mohamed R, Ning Q, Rahman S, Rastogi A, Riordan SM, Sakhuja P, Samuel D, Shah S, Sharma BC, Sharma P, Takikawa Y, Thapa BR, Wai CT, Yuen MF. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int 2009, 3:269-282. 10.1007/s12072-008-9106-x, 2712314, 19669378.
9. Sen S, Williams R, Jalan R. The pathophysiological basis of acute-on-chronic liver failure. Liver 2002, 22:5-13. 10.1034/j.1600-0676.2002.00001.x, 12220296.
10. Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V. Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr 2009, 121:732-744. 10.1007/s00508-009-1288-2, 20047110.
11. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009, 51:475-482. 10.1016/j.jhep.2009.04.017, 19560225.
12. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006, 26:1175-1186. 10.1111/j.1478-3231.2006.01342.x, 17105582.
13. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006, 12:7413-7420.
14. Heymann F, Trautwein C, Tacke F. Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets 2009, 8:307-318. 10.2174/187152809789352230, 19534673.
15. Prins HA, Meijer C, Boelens PG, Diks J, Holtz R, Masson S, Daveau M, Meijer S, Scotté M, van Leeuwen PA. Kupffer cell-depleted rats have a diminished acute-phase response following major liver resection. Shock 2004, 21:561-565. 10.1097/01.shk.0000126649.96850.36, 15167686.
16. Sakamoto S, Okanoue T, Itoh Y, Nakagawa Y, Nakamura H, Morita A, Daimon Y, Sakamoto K, Yoshida N, Yoshikawa T, Kashima K. Involvement of Kupffer cells in the interaction between neutrophils and sinusoidal endothelial cells in rats. Shock 2002, 18:152-157. 10.1097/00024382-200208000-00011, 12166779.
17. Jaeschke H, Farhood A. Kupffer cell activation after no-flow ischemia versus hemorrhagic shock. Free Radic Biol Med 2002, 33:210-219. 10.1016/S0891-5849(02)00867-5, 12106817.
18. Pimentel-Nunes P, Roncon-Albuquerque R, Gonçalves N, Fernandes-Cerqueira C, Cardoso H, Bastos RP, Marques M, Marques C, Alexandre Sarmento J, Costa-Santos C, Macedo G, Pestana M, Dinis-Ribeiro M, Leite-Moreira AF. Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease. Liver Int 2010, 30:1003-1011. 10.1111/j.1478-3231.2010.02251.x, 20492495.
19. Stadlbauer V, Shah N, de Oca Arjona MM, Mookerjee RP, Jalan R. Alcohol takes the toll on immune function. Liver Int 2010, 30:934-936. 10.1111/j.1478-3231.2010.02271.x, 20492504.
20. Stadlbauer V, Mookerjee RP, Wright GA, Davies NA, Jürgens G, Hallström S, Jalan R. Role of Toll-like receptors 2,4 and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastroinstest Liver Physiol 2009, 296(1):G15-22.
21. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008, 48:322-335. 10.1002/hep.22306, 18506843.
22. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010, 16:1321-1329. 10.3748/wjg.v16.i11.1321, 2842523, 20238398.
23. Yoshimura A, Lien E, Ingalls RR, Tuomanen E, Dziarski R, Golenbock D. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999, 163:1-5.
24. Steib CJ, Bilzer M, Härtl JM, Beitinger F, Gülberg V, Göke B, Gerbes AL. Kupffer cell activation by hydrogen peroxide: a new mechanism of portal pressure increase. Shock 2010, 33:412-418. 10.1097/SHK.0b013e3181b85934, 20118678.
25. Antoniades CG, Berry PA, Wendon JA, Vergani D. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 2008, 49:845-861. 10.1016/j.jhep.2008.08.009, 18801592.
26. Vollmar B, Menger MD. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009, 89:1269-1339. 10.1152/physrev.00027.2008, 19789382.
27. Steinhoff G, Behrend M, Schrader B, Duijvestijn AM, Wonigeit K. Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia Lack of ELAM-1 and CD62 inducibility on sinusoidal endothelia and distinct distribution of VCAM-1, ICAM-1, ICAM-2 and LFA-3. Am J Pathol 1993, 142:481-488. 1886730, 8434643.
28. Rockey DC, Fouassier L, Chung JJ, Carayon A, Vallee P, Rey C, Housset C. Cellular localization of endothelin-1 and increased production in liver injury in the rat: potential for autocrine and paracrine effects on stellate cells. Hepatology 1998, 27:472-480. 10.1002/hep.510270222, 9462646.
29. Steib CJ, Hartmann AC, v Hesler C, Benesic A, Hennenberg M, Bilzer M, Gerbes AL. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest 2010, 90:1024-1032. 10.1038/labinvest.2010.60, 20212458.
30. Brubaker J, Montaner LJ. Role of interleukin-13 in innate and adaptive immunity. Cell Mol Biol 2001, 47:637-651.
31. Lee CG, Homer RJ, Zhu Z, Lanone S, Wang X, Koteliansky V, Shipley JM, Gotwals P, Noble P, Chen Q, Senior RM, Elias JA. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta. J Exp Med 2001, 194:809-821. 10.1084/jem.194.6.809, 2195954, 11560996.
32. Lin CY, Tsai IF, Ho YP, Huang CT, Lin YC, Lin CJ, Tseng SC, Lin WP, Chen WT, Sheen IS. Endotoxinemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007, 46:816-826. 10.1016/j.jhep.2006.12.018, 17328986.
33. Wasmuth HE, Kunz D, Yagmur E, Timmer-Stranghöner A, Vidacek D, Siewert E, Bach J, Geier A, Purucker EA, Gressner AM, Matern S, Lammert F. Patients with acute on chronic liver failure display 'sepsis-like' immune paralysis. J Hepatol 2005, 42:195-201.
34. Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006, 45:280-289. 10.1016/j.jhep.2006.02.013, 16635535.
35. Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard B, Opolon P, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 2000, 32:579-586. 10.1016/S0168-8278(00)80219-6, 10782906.
36. Stanley AJ, MacGregor IR, Dillon JF, Bouchier IA, Hayes PC. Neutrophil activation in chronic liver disease. Eur J Gastroenterol Hepatol 1996, 8:135-138. 10.1097/00042737-199602000-00008, 8723417.
37. Neugebauer H, Hartmann P, Krenn S, Glück T, Schölmerich J, Straub R, Wiest R. Bacterial translocation increases phagocytic activity of polymorphonuclear leucocytes in portal hypertension: priming independent of liver cirrhosis. Liver Int 2008, 28:1149-1157. 10.1111/j.1478-3231.2008.01829.x, 18662280.
38. Feliu E, Gougerot MA, Hakim J, Cramer E, Auclair C, Rueff B, Boivin P. Blood polymorphonuclear dysfunction in patients with alcoholic cirrhosis. Eur J Clin Invest 1977, 7:571-577. 10.1111/j.1365-2362.1977.tb01653.x, 415878.
39. Abrahám S, Szabó A, Kaszaki J, Varga R, Eder K, Duda E, Lázár G, Tiszlavicz L, Boros M, Lázár G. Kupffer cell blockade improves the endotoxin-induced microcirculatory inflammatory response in obstructive jaundice. Shock 2008, 30:69-74.
40. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994, 20:453-460. 10.1002/hep.1840200227, 8045507.
41. Michael SL, Pumford NR, Mayeux PR, Niesman MR, Hinson JA. Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 1999, 30:186-195. 10.1002/hep.510300104, 10385655.
42. Mandal P, Pritchard MT, Nagy LE. Anti-inflammatory pathways and alcoholic liver disease: Role of an adiponectin/interleukin-10/heme-oxygenase-1 pathway. World J Gastroenterol 2010, 16:1330-1336. 10.3748/wjg.v16.i11.1330, 2842524, 20238399.
43. Szabo G, Mandrekar P, Girouard L, Catalano D. Regulation of human monocyte functions by acute ethanol treatment: decreased tumor necrosis factor-α, interleukin-1β and elevated interleukin-10, and transforming growth factor-β production. Alcohol Clin Exp Res 1996, 20:900-907. 10.1111/j.1530-0277.1996.tb05269.x, 8865966.
44. Addolorato G, Russell M, Albano E, Haber PS, Wands JR, Leggio L. Understanding and treating patients with alcoholic cirrhosis: an update. Alcohol Clin Exp Res 2009, 33:1136-1144. 10.1111/j.1530-0277.2009.00956.x, 19389182.
45. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009, 130:16-26. 10.1016/j.clim.2008.08.008, 18823822.
46. Suh YG, Jeong WI. Hepatic stellate cells and innate immunity in alcoholic liver disease. World J Gastroenterol 2011, 17:2543-51. 10.3748/wjg.v17.i20.2543, 3103812, 21633659.
47. Bellot P, García-Pagán JC, Francés R, Abraldes JG, Navasa M, Pérez-Mateo M, Such J, Bosch J. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology 2010, 52:2044-2052. 10.1002/hep.23918, 20979050.
48. Guarner C, González-Navajas JM, Sánchez E, Soriando G, Francés R, Chiva M, Zapater P, Benlloch S, Muñoz C, Pascual S, Balanzó J, Pérez-Mateo M, Such J. The detection of bacterial DNA in blood of rats with CCl4-induced cirrhosis with ascites represents episodes of bacterial translocation. Hepatology 2006, 44:633-639.
49. Cárdenas A, Ginès P. Acute-on-chronic liver failure: the kidneys. Curr Opin Crit Care 2011, 17:184-189. 10.1097/MCC.0b013e328344b3da, 21311322.
50. Lebrec D, Thabut D, Oberti F, Perarnau JM, Condat B, Barraud H, Saliba F, Carbonell N, Renard P, Ramond MJ, Moreau R, Poynard T, . Pentocir Group Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010, 138:1755-1762. 10.1053/j.gastro.2010.01.040, 20102716, Pentocir Group.
51. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:1637-1648. 10.1053/gast.2000.20189, 11113085.
52. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003, 38:419-425.
53. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-559. 10.1038/nm1589, 17479101.
54. Garcia-Tsao G. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18:353-372. 10.1016/j.bpg.2003.10.005, 15123075.
55. Wiest R, Garcia-Tsao G. Bacterial translocation in cirrhosis. Hepatology 2005, 41:422-433. 10.1002/hep.20632, 15723320.
56. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993, 17:1081-1085. 10.1002/hep.1840170622, 8514258.
57. Cirera I, Bauer TM, Navasa M, Vila J, Grande L, Taurá P, Fuster J, García-Valdecasas JC, Lacy A, Suárez MJ, Rimola A, Rodés J. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001, 34:32-37.
58. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995, 108:1835-1841. 10.1016/0016-5085(95)90147-7, 7768390.
59. Sorell WT, Quigley EM, Jin G, Johnson TJ, Rikkers LF. Bacterial translocation in the portal-hypertensive rat: studies in basal condition and on exposure to hemorrhagic shock. Gastroenterology 1993, 104:1722-1726.
60. Such J, Francés R, Muñoz C, Zapater P, Casellas JA, Cifuentes A, Rodríguez-Valera F, Pascual S, Sola-Vera J, Carnicer F, Uceda F, Palazón JM, Pérez-Mateo M. Detection and identifi cation of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology 2002, 36:135-141.
61. Wang W, Smail N, Wang P, Chaudry IH. Increased gut permeability after hemorrhage is associated with upregulation of local and systemic IL-6. J Surg Res 1998, 79:39-46. 10.1006/jsre.1998.5385, 9735238.
62. Steffen EK, Berg RD, Deitch EA. Comparison of translocation rates of various indigenous bacteria from the gastrointestinal tract to the mesenteric lymph node. J Infect Dis 1988, 157:1032-1038. 10.1093/infdis/157.5.1032, 3283254.
63. Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE. Small intestinal overgrowth and bacterial translocation in human cirrhosis is associated with systemic endotoxinemia. Am J Gastroenterol 2002, 97:2364-2370. 10.1111/j.1572-0241.2002.05791.x, 12358257.
64. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 1998, 28:1187-1190. 10.1002/hep.510280504, 9794900.
65. Teshima CW, Meddings JB. The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep 2008, 10:443-449. 10.1007/s11894-008-0083-y, 18799118.
66. Pascual S, Such J, Esteban A, Zapater P, Casellas JA, Aparicio JR, Girona E, Gutiérrez A, Carnices F, Palazón JM, Sola-Vera J, Pérez-Mateo M. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology 2003, 50:1482-1486.
67. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002, 35:622-629. 10.1053/jhep.2002.31656, 11870376.
68. Wong F, Bernardi M, Balk R, Christman B, Moreau R, Garcia-Tsao G, Patch D, Soriano G, Hoefs J, Navasa M, . International Ascites Club Sepsis in cirrhosis: report on the 7th meeting of the international ascites club. Gut 2005, 54:718-725. 10.1136/gut.2004.038679, 1774473, 15831923, International Ascites Club.
69. Tazi KA, Moreau R, Hervé P, Dauvergne A, Cazals-Hatem D, Bert F, Poirel O, Rabiller A, Lebrec D. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005, 129:303-314. 10.1053/j.gastro.2005.04.016, 16012955.
70. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, Raptis S, Karamanolis DG. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009, 29:992-999. 10.1111/j.1365-2036.2009.03958.x, 19210289.
71. Cesaro C, Tiso A, Del Prete A, Cariello R, Tuccillo C, Cotticelli G, Del Vecchio Blanco C, Loguercio C. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis 2011, 43:431-438. 10.1016/j.dld.2010.10.015, 21163715.
72. Martin PY, Xu DL, Niederberger M, Weigert A, Tsai P, St John J, Gines P, Schrier RW. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol 1996, 270:F494-499.
73. Fernández M, García-Pagán JC, Casadevall M, Bernadich C, Piera C, Whittle BJ, Piqué JM, Bosch J, Rodés J. Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal hypertensive rats. Gastroenterology 1995, 108:1487-1495. 10.1016/0016-5085(95)90698-3, 7537235.
74. Cahill PA, Redmond EM, Hodges R, Zhang S, Sitzmann JV. Increased endothelial nitric oxide synthase activity in the hyperemic vessels of portal hypertensive rats. J Hepatol 1996, 25:370-378. 10.1016/S0168-8278(96)80124-3, 8895017.
75. Tazi KA, Barrière E, Moreau R, Heller J, Sogni P, Pateron D, Poirel O, Lebrec D. Role of shear stress in aortic eNOS up-regulation in rats with biliary cirrhosis. Gastroenterology 2002, 122:1869-1877. 10.1053/gast.2002.33586, 12055594.
76. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999, 104:1223-1233. 10.1172/JCI7458, 409820, 10545521.
77. Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005, 25:1079-1090. 10.1111/j.1478-3231.2005.01163.x, 16343056.
78. Pannen BH, Bauer M, Nöldge-Schomburg GF, Zhang JX, Robotham JL, Clemens MG, Geiger KK. Regulation of hepatic blood flow during resuscitation from hemorrhagic shock: role of NO and endothelins. Am J Physiol 1997, 272:H2736-2745.
79. Steib CJ, Bilzer M, op den Winkel M, Pfeiler S, Hartmann AC, Hennenberg M, Göke B, Gerbes AL. Treatment with the leukotriene inhibitor montelukast for 10 days attenuates portal hypertension in rat liver cirrhosis. Hepatology 2010, 51:2086-2096. 10.1002/hep.23596, 20512996.
80. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007, 132:709-719. 10.1053/j.gastro.2006.12.041, 17258737.
81. Rockey DC. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337-349. 10.1055/s-2001-17551, 11586464.
82. Laleman W, Van Landeghem L, Severi T, Vander Elst I, Zeegers M, Bisschops R, Van Pelt J, Roskams T, Cassiman D, Fevery J, Nevens F. Both Ca2+-dependent and independent pathways are involved in rat hepatic stellate cell contraction and intrahepatic hyperresponsiveness to methoxamine. Am J Physiol Gastrointest Liver Physiol 2007, 292:G556-564.
83. Baveja R, Kresge N, Ashburn JH, Keller S, Yokoyama Y, Sonin N, Zhang JX, Huynh T, Clemens MG. Potentiated hepatic microcirculatory response to endothelin-1 during polymicrobial sepsis. Shock 2002, 18:415-422. 10.1097/00024382-200211000-00005, 12412619.
84. Pannen BH, Bauer M, Zhang JX, Robotham JL, Clemens MG. Endotoxin pretreatment enhances portal venous contractile response to endothelin-1. Am J Physiol 1996, 270:H7-H15.
85. Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992, 326:507-512. 10.1056/NEJM199202203260802, 1531090.
86. Rafailidis S, Ballas K, Psarras K, Pavlidis T, Emoniotou E, Papamichali R, Kalodimos G, Marakis G, Sakadamis A, Koukoulis G. Effect of early bosentan administration on the development of esophageal varices in cirrhotic rats: experimental study in Wistar rats. J Gastroenterol 2008, 43:897-904. 10.1007/s00535-008-2243-0, 19012044.
87. Sogni P, Moreau R, Gomola A, Gadano A, Cailmail S, Calmus Y, Clozel M, Lebrec D. Benificial hemodynamic effects of bosentan, a mixed ET(A) and ET(B) receptor antagonist, in portal hypertensive rats. Hepatology 1998, 28:655-659. 10.1002/hep.510280308, 9731554.
88. Reichen J, Gerbes AL, Steiner MJ, Sägesser H, Clozel M. The effect of endothelin and its antagonist bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J Hepatol 1998, 28:1020-1030. 10.1016/S0168-8278(98)80352-8, 9672179.
89. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007, 30:338-344. 10.1183/09031936.00138706, 17504794.
90. Hoeper MM, Halank M, Marx C, Hoeffken G, Seyfarth HJ, Schauer J, Niedermeyer J, Winkler J. Bosentan therapy for portopulmonary hypetension. Eur Respir J 2005, 25:502-508. 10.1183/09031936.05.00080804, 15738295.
91. Urbanowicz W, Sogni P, Moreau R, Tazi KA, Barriere E, Poirel O, Martin A, Guimont MC, Cazals-Hatem D, Lebrec D. Tezosentan, an endothelin receptor antagonist, limits liver injury in endotoxin challenged cirrhotic rats. Gut 2004, 53:1844-1849. 10.1136/gut.2003.036517, 1774327, 15542526.
92. Van de Casteele M, Omasta A, Janssens S, Roskams T, Desmet V, Nevens F, Fevery J. In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthesised carbon tetrachloride cirrhotic rats. Gut 2002, 51:440-445. 10.1136/gut.51.3.440, 1773350, 12171971.
93. Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuto G, Clerici C, Baldoni M, Del Soldato P, Morelli A. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003, 39:940-946. 10.1016/j.jhep.2003.09.018, 14642609.
94. Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Am J Gastroenterol 2010, 105:1094-1101. 10.1038/ajg.2009.661, 19920806.
95. Zafra C, Abraldes JG, Turnes J, Berzigotti A, Fernández M, Garca-Pagán JC, Rodés J, Bosch J. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004, 126:749-755. 10.1053/j.gastro.2003.12.007, 14988829.
96. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet 2006, 367:413-418. 10.1016/S0140-6736(06)68041-0, 16458766.
97. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care 2010, 25:656.e7-22. 10.1016/j.jcrc.2010.02.013, 20413251.
98. Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Knawy BA, Hajeer AH, Tamimi W, Cherfan A. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ 2010, 182:1971-1977. 10.1503/cmaj.090707, 3001503, 21059778.
99. Laleman W, Wilmer A, Evenepoel P, Elst IV, Zeegers M, Zaman Z, Verslype C, Fevery J, Nevens F. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006, 10:R108. 10.1186/cc4985, 1751025, 16859530.
100. Laleman W, Wilmer A, Evenepoel P. Review article: non-biological liver support in liver failure. Aliment Pharmacol Ther 2006, 23:351-363. 10.1111/j.1365-2036.2006.02765.x, 16422994.